Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.24.00645 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Ying-Chun Shen und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Hauptthemen laut MEDLINE: Bevacizumab, Liver Neoplasms, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these patients and the histopathology of the residual tumors. PATIENTS AND METHODS The IMbrave150 study's atezo-bev group was analyzed. PR or SD per RECIST v1.1 lasting more than 6 months was defined as durable. For histologic analysis, a comparable real-world group of patients from Japan and Taiwan who had undergone resection of residual tumors after atezo-bev was investigated. RESULTS In the IMbrave150 study, 56 (77.8%) of the 72 PRs and 41 (28.5%) of the 144 SDs were considered durable. The median overall survival was not estimable for patients with durable PR and 23.7 months for those with durable SD. The median progression-free survival was 23.2 months for patients with durable PR and 13.2 months for those with durable SD. In the real-world setting, a total of 38 tumors were resected from 32 patients (23 PRs and nine SDs) receiving atezo-bev. Pathologic complete responses (PCRs) were more frequent in PR tumors than SD tumors (57.7% v 16.7%, P = .034). PCR rate correlated with time from atezo-bev initiation to resection and was 55.6% (5 of 9) for PR tumors resected beyond 8 months after starting atezo-bev, a time practically corresponding to the durable PR definition used for IMbrave150. We found no reliable radiologic features to predict PCR of the residual tumors. CONCLUSION Durable PR patients from the atezo-bev group showed a favorable outcome, which may be partly explained by the high rate of PCR lesions. Early recognition of PCR lesions may help subsequent treatment decision.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Genentech, Inc, South San Francisco, CA.
- Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan.
ORCID-Profile: Ying-Chun Shen, Tsung-Hao Liu, Tomoharu Yoshizumi, Shinji Itoh, Masaki Kaibori, Takamichi Ishii, Etsuro Hatano, Chikara Ogawa, Atsushi Naganuma, Satoru Kakizaki, Chih-Hsien Cheng, Yung-Yeh Su, Chien-Huai Chuang, Li-Chun Lu, Hung-Wei Wang, Kun-Ming Rau, Chih-Hung Hsu, Yi-Hsiang Huang, Richard S Finn, Masatoshi Kudo, Ann-Lii Cheng
Förderung
- NCI NIH HHS
Zitieren
APA
Shen, Y. C., Liu, T. H., Nicholas, A., Soyama, A., Yuan, C. T., Chen, T. C., Eguchi, S., Yoshizumi, T., Itoh, S., Nakamura, N., Kosaka, H., Kaibori, M., Ishii, T., Hatano, E., Ogawa, C., Naganuma, A., Kakizaki, S., Cheng, C. H., Lin, P. T., …, & Cheng, A. L. (2024). Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00645
Vancouver
Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, et al. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00645
BibTeX
@article{Shen2024,
author = {Shen, Ying-Chun and Liu, Tsung-Hao and Nicholas, Alan and Soyama, Akihiko and Yuan, Chang-Tsu and Chen, Tse-Ching and Eguchi, Susumu and Yoshizumi, Tomoharu and Itoh, Shinji and Nakamura, Noriaki and Kosaka, Hisashi and Kaibori, Masaki and Ishii, Takamichi and Hatano, Etsuro and Ogawa, Chikara and Naganuma, Atsushi and Kakizaki, Satoru and Cheng, Chih-Hsien and Lin, Po-Ting and Su, Yung-Yeh and Chuang, Chien-Huai and Lu, Li-Chun and Wu, Chi-Jung and Wang, Hung-Wei and Rau, Kun-Ming and Hsu, Chih-Hung and Lin, Shi-Ming and Huang, Yi-Hsiang and Hernandez, Sairy and Finn, Richard S and Kudo, Masatoshi and Cheng, Ann-Lii},
title = {Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.24.00645}
}
EUVIMED